Women’s imaging manufacturer Hologic Inc. has completed its $6.2 billion acquisition of women’s health products supplier Cytyc Corp.

Under terms of the deal, Cytyc shareholders received 0.52 shares of Hologic common stock and $16.50 in cash for each share of Cytyc common stock held by them.

The $6.2 billion aggregate consideration was payable in approximately 65.8 million shares of Hologic common stock and about $2.1 billion in cash.

“By combining our companies’ complementary, best-in-class products and technologies, we expect to drive enhanced growth and value creation,” said Jack Cumming, Hologic’s chief executive officer. “We are now focused on seamlessly integrating these two great companies and realizing the tremendous upside potential our combination creates.”

Hologic will continue to trade on the Nasdaq Global Select Market under the symbol “HOLX.”

As a wholly owned subsidiary of Hologic, Cytyc ceased trading on the NASDAQ as of yesterday.